Our Recent partnership with Atheropoint

Introducing For the first time in Nigeria

Monitoring Made Simple.
*Key features*
. Non-invasive
. No radiation
. Simple ultrasound
. Prevents Stroke Risk
. Prevent Coronary Disease risk
. Automated and Fast processing
Early Atherosclerosis Disease Monitoring to Prevents Stroke and Coronary Artery Disease.
*Scanning For Patients with:
# Smoking
# Obesity
# Diabetes
# High A1c
# High Lipids
# Existing CVD
# Stressful Life
# Hypertension
# Age > 45 Years
# Sedentary Life Styles
# Erectile Dysfunction
# History of Heart Disease.



. Cardiologist
. Neurologist
. Endocrinologist
. Radiologists
. Bariatricians
. Internist
Others who will benefit also Are:
. Psychotherapists
. Psychologists.
Original Articles, Accurate cloud based smart IMT measurement, it’s validation and stroke risk stratification in carotid ultrasound : A web- based point – of – care tool for multi center clinical trials.
Healthstead Global Limited:
We Are the main partner of AtheroPoint in Nigeria a fully equipped and dedicated center in Nigeria.



High O2 consumption, modest antioxidant defenses and a lipid-rich constitution make the brain highly vulnerable to redox imbalances. Oxidative damage in the brain causes nervous system impairment. Recently, oxidative stress has also been implicated in depression, anxiety disorders and high anxiety levels. The findings which establish a link between oxidative stress and pathological anxiety have inspired a number of other recent studies focusing on the link between oxidative status and normal anxiety and also on a possible causal relationship between cellular oxidative stress and emotional stress. This review examines the recent discoveries made on the link between oxidative status and normal anxiety levels and the putative role of oxidative stress in genesis of anxiety. We discuss the different opinions and questions that exist in the field and review the methodological approaches that are being used to determine a causal relationship between oxidative and emotional stress.

Key words: anxiety, behavior, oxidative status, oxidative stress, reactive oxygen species, antioxidants


Anxiety is an aversive emotional state, in which the feeling of fear is disproportionate to the nature of the threat.1 In response to threatening situations, the feeling of the emotion that constitutes the subjective feature of anxiety is accompanied by emotional stress, which involves behavioral, expressive and physiological features, such as an avoidance of the source of the danger, assuming defensive postures and an increase in blood pressure, respectively.1,2 Anxiety is a normal emotional response to a threat or potential threat. When this emotion is inappropriate, extreme and persistent, it is classified as pathological.1,3 Anxiety is implicated in a number of psychiatric disorders, such as depression, panic attacks, phobias, generalized anxiety disorder, obsessive-compulsive disorder and post-traumatic stress disorder.3Anxiety disorders affect approximately 28.8% of the US population,4 imposing both an individual and a social burden that amounts to a total cost of $42.3 billion in the US in 1990.5 Anxiety disorders are the most common class of psychiatric disorders in the US4 and many other countries.6According to an ESEMeD study including six European countries, the 12-month prevalence of inappropriate anxiety was 6.4%.7 In the most recent systematic review of studies conducted in 16 European countries, however, this value was estimated to be 12%.8 In an obese population in the UK, 56% of patients met the minimum criteria for an anxiety disorder.9 It is estimated that one-eighth of the total population worldwide suffers from inappropriate anxiety.10 Population-based studies have shown that anxiety disorders frequently go untreated.11,12 Predominantly, the research that has been performed on anxiety has focused on the regulatory systems, including gamma-aminobutyric acidergic (GABAergic) and serotoninergic systems among others. However, Kuloglu et al.13,14 recently established a link between oxidative stress and certain anxiety disorders (obsessive-compulsive disorder and panic disorder), demonstrating that other systems, such as oxidative metabolism, can affect the regulation of anxiety. These findings, which establish a link between oxidative stress and pathological anxiety, inspired a number of other recent studies focusing on the link between oxidative status and normal anxiety (Table 1) and also on a possible causal relationship between cellular oxidative stress and emotional stress.

Table 1

Data establishing the link between pathological/normal anxiety and oxidative cell pathways and mechanisms

It is well known that low/moderate concentrations of reactive oxygen species (ROS) affect a great number of physiological functions.15However, when ROS concentration exceeds the anti-oxidative capacity of an organism, animal cells enter a state termed oxidative stress, in which the excess ROS induces oxidative damage on cellular components.15,16 As a result, oxidative stress has been implicated in a large range of diseases, including cancer, diabetes, male infertility, autoimmune diseases, atherosclerosis and cardiovascular disorders.1517

The brain is highly vulnerable to oxidative stress due to its high O2consumption, its modest antioxidant defenses and its lipid-rich constitution.18,19 Human brain utilizes 20% of oxygen consumed by the body even though this organ constitutes only about 2% of the body weight.19,20 When the production of oxygen-derived metabolites prevails over the brain defense systems, however, oxidative damage to nucleic acids, proteins and neuronal membrane lipids, which are rich in highly polyunsaturated fatty acids, can occur.15,16,19 In presence of oxidative stress, the lipid-rich constitution of brain favors lipid peroxidation that results in decrease in membrane fluidity and damage in membrane proteins inactivating receptors, enzymes and ion channels.15,16,19 As a result, oxidative stress can alter neurotransmission, neuronal function and overall brain activity.16,21,22 Oxidative stress has been associated with several diseases which are specific for nervous system impairment including neurodegenerative diseases and neuropsychiatric diseases, such as schizophrenia and major depressive disorder.15,16,23,24 The intrinsic oxidative vulnerability of the brain has led some authors to suggest that oxidative damage may be a plausible pathogenic factor for certain neurological diseases including neuropsychiatric disorders.18

In this review, we discuss the relationship between oxidative stress and normal anxiety by presenting the recent advances in the field and the different views that exist. We also review the methodological approach for determining the causal relationship between oxidative stress and emotional stress.

A Link Between Oxidative Stress Metabolic Pathways and Anxiety-Related Phenotypes

In 2005, Hovatta et al.25 identified a close relationship between antioxidative defense mechanisms and anxiety-related phenotypes in six inbred mouse strains. They found that, in the brain, the expression of glutathione reductase 1 and glyoxalase 1, which are genes involved in antioxidative metabolism, is highly correlated with anxiety-related phenotypes. Furthermore, they also found that the activity of these enzymes is highest in the most anxious mice and lowest in the least anxious strains. These authors were the first to demonstrate a link between oxidative stress metabolic pathways and normal anxiety.

A link between oxidative stress and emotional stress is not surprising, since it is well accepted that oxidative damage in the brain causes an impairment of the nervous system. In living organisms, an imbalance between oxidant production and antioxidant protection that favors oxidants causes a state termed oxidative stress. In this state, there can be differences gene expression, protein conformation and cellular signaling. This state may also alter neurotransmission, neuronal function and overall brain activity, as well as disrupting membrane integrity; even neuronal cell death may result.15,16,21,22 Most studies have shown that anxiety is controlled by the nervous system and that GABAergic and serotoninergic systems play important roles in the regulation of anxiety.1,26 Abnormalities in these regulatory systems in rodents, which are used as translational models for human anxiety,25,27,28can result in anxious behavior.26Altering the function of the hypothalamic-pituitary-adrenal (HPA) axis, which is implicated in stress responses29 and anxiety disorders, could also impact the emotional response.29,30

Nevertheless, Hovatta et al.25obtained surprising results in a genetic manipulation using lentivirus-mediated gene transfer: local overexpression of glutathione reductase 1 and glyoxalase 1 in the cingulated cortex of the murine brain results in an increase of anxiety-like behavior, while inhibition of glyoxalase 1 expression produces low-anxiety mice. Thus, Hovatta et al.25 were able to make a causal link between the antioxidative status of the brain and anxiety-related behavior and hypothesize that glyoxalase 1 and glutathione reductase 1 regulate anxiety in mice. It is worth mentioning that in vivo, antioxidant genes are overexpressed in response to an uncontrolled production of ROS. Indeed, in vivo, excessive ROS accumulation induces the overexpression of the glutathione redox system, including glutathione reductase, and a general overexpression of endogenous antioxidants.31,32 In the lentivirus experiments of Hovatta et al.25, however, the overexpression of the transgenes (glyoxalase 1 and glutathione reductase 1) was induced in vivo with a lentiviral vector and not an excessive production of toxic oxygen metabolites. Clearly, the mechanism by which these enzymes regulate anxiety is of great interest.26

During the same period in which the Hovatta et al.25 study was being conducted, other studies were performed on two Swiss CD1 mouse lines with contrasting anxiety-like behavioral phenotypes. These mice were generated from wild type mice after >15 generations of selection. Results from these studies have led researchers to propose that glyoxalase 1 might be a biological marker for trait anxiety.33,34 These results are discordant with those of Hovatta et al.25 however, and complicate the understanding of the relationship between oxidative stress and trait anxiety. Krömer et al.33 and Ditzen et al.34 examined the expression of glyoxalase 1 in several areas of the brain areas and in red blood cells and found that this protein is expressed more in a line with a low-anxiety-related behavioral phenotype than in a line with a high-anxiety-related behavioral phenotype. It is worth noting that Hovatta et al.25suggested that there is a link between glyoxalase 1 and oxidative stress but that this link is indirect.35Indeed, glyoxalase 1 is an enzyme of the glyoxalase system, which protects against carbonyl stress; glutathione is a determinant cofactor for the enzymatic reaction that is catalyzed by glyoxalase 1.3537

A Link Between Oxidative Stress Metabolic Pathways and Anxiety-Related Behavior

The disagreements in the data of Hovatta et al.25, Krömer et al.33 and Ditzen et al.34 can be partly explained by the differences in the genotypes of the strains.35 Thus, it would be interesting to compare in the same strain the oxidative status of mice with contrasting levels of anxiety, rather than compare the oxidative status of strains that differ in their anxiety-related phenotypes. We have observed that naive Swiss albino male mice have a large heterogeneity in their anxiety levels.38 In first order regression analyses of the performances of mice in the light/dark choice test, which are used as a behavioral indices of anxiety, and the intracellular ROS accumulation in blood granulocytes, we found correlation coefficients (R2) ranging from 0.61 (p < 0.01) to 0.73 (p < 0.001) (Fig. 1). Our results suggest that there is a positive correlation between peripheral blood cell oxidative status and anxiety-related behavior in the light/dark box in Swiss albino male mice.38

Figure 1

Linear correlation between intracellular redox status and different parameters used for assessment of anxiety-related behavior in mice (n = 18). Correlation of peripheral blood granulocyte oxidative status with latency of first crossing from dark to lit

Levels of ROS can be evaluated directly with sensors, such as 2′,7′-dichlorofluorescin diacetate (DCFH-DA),39,40 or indirectly by measuring the levels of certain antioxidant enzymes, byproducts of lipid peroxidation or some transition metals, such as copper, zinc and iron.13,14 In our study, the intracellular redox status of the cells was evaluated using the tracer DCFH-DA, a well known sensor of ROS.39,40 To confirm the relationship between oxidative stress and emotional stress, we comparatively evaluated the peripheral oxidative status of mice with contrasting levels of anxiety (anxious and non-anxious). Mice with intermediate behaviors were eliminated.41 We found that high anxiety in mice in the light-dark box is accompanied by significantly high levels of intracellular ROS in lymphocytes, granulocytes and monocytes (Table 2). Our results confirm that there is the relationship between the level of intracellular ROS in peripheral blood cells and anxiety-related behavior in mice.41

Table 2

Intracellular ROS accumulation in peripheral immune cells of anxious and non-anxious mice

These results prompted us to study the oxidative status of the brain in mice with contrasting levels of anxiety. Using the same behavioral approach to distinguish between anxious and non-anxious mice, we found that anxiety in mice is accompanied by markedly elevated levels of ROS in neuronal and glial cells within the cerebellum and hippocampus, as well as in neurons of the cerebral cortex and in blood monocytes, granulocytes and lymphocytes (Table 3). As a consequence, we suggest that an imbalance in the redox system of anxious mice plays a role in neuroinflammation and neurodegeneration, predisposing them to recurrent infection and chronic inflammation.42 The results of our studies38,41,42 are in good concordance with the initial findings of Hovatta et al.25 and show a clear link between oxidative stress and trait anxiety, but our findings do not permit us to declare a causal relationship between these stresses.

Table 3

Intracellular ROS accumulation in cerebral and peripheral cells of anxious and non-anxious mice

In agreement with our recent findings,41,42 Yasunari et al.43observed a significant relationship between trait anxiety and ROS formation in monocytes of hypertensive individuals. Recently, Masood et al.29 published work that contributes to the understanding of the relationship between oxidative stress and anxiety. They examined the direct effect of oxidative stress on anxiety-like behavior and established that oxidative stress leads to anxiogenic behavior in mice. They found that treating mice with buthionine-S,R-sulfoximine (BSO), an inducer of oxidative stress, induces anxious behavior through the NADPH oxidase pathway. The anxiogenic behavior due to BSO treatment was observed in several mouse models of anxiety, including elevated plus maze, hole-board and open field tests. Masood et al.29induced oxidative stress in mice by depleting glutathione with BSO inhibition of gamma-glutamylcysteine synthetase. Glutathione depletion causes a myriad of cellular stresses, including oxidative, nitrosative and carbonyl stresses, as glutathione is an important determinant of the oxygen, nitrogen and dicarbonyl metabolisms.15,16,35,44 Excessive production of ROS induces oxidative damage of cellular structures;15,16,19,45 production of reactive nitrogen species triggers nitrosylation reactions, which can alter the structure of proteins to inhibit their normal function;15,16,46 excessive accumulation of reactive dicarbonyl compounds leads to damage of protein and nucleotides by dicarbonyl glycation.3537

Indirect Evidence for the Causal Link Between Oxidative Stress and Anxiety

Recent data from Desrumaux et al.47, Souza et al.48 and Berry et al.49 provide indirect evidence for the causal link between oxidative stress and anxiety-related behavior. Desrumaux et al.47 showed that vitamin E deficiency in the mouse brain significantly increases the levels of central oxidative stress markers, resulting in anxiogenic behavior without abnormalities in the locomotor performance of the mice. Souza et al.48 demonstrated in rats that the consumption of a highly palatable diet enriched with sucrose leads to an obese phenotype, increases protein oxidation in the frontal cortex and induces anxiety-like behavior in the dark/light choice test without altering locomotion in an open field test. Berry et al. showed that mice developed anxious behavior during aging, likely due to the accumulation of oxidative damage, which is a characteristic of the aging process in animals. In addition, Berry et al. showed that a deletion of the p66Shc longevity gene in mice, which results in lower levels of oxidative stress and an extended life span, decreases anxiety-related behavior. Overall, the data presented in these reports suggest that oxidative stress can provoke anxious behavior in rodents.


This review summarizes the data to support a link between oxidative stress and anxiety. While all of the data demonstrate that there is a link between oxidative stress and high-anxiety-related behavior, a cause-effect relationship has yet to be completely established. Some of these studies suggest that oxidative stress causes anxiety-related behaviors but do not explain the underlying mechanisms. While there are some limits in the approach to establish the anxiogenic effect of oxidative stress, the available data are consistent this causal relationship. The potential causal role of oxidative stress on anxiety may generate interest in antioxidants. Masood et al.29 were able to show that oxidative stress-related anxiety can be reversed in mice upon inhibition of NADPH oxidase or phosphodiesterase-2, enzyme that is indirectly implicated in oxidative stress mechanisms. Surprisingly, they found that diazepam, which is a well known anxiolytic, does not fully reverse the oxidative stress-related anxiety. These results point to a possible use for antioxidants in the prevention or reduction of high anxiety. Further research will be necessary to show whether anxious subjects need more antioxidants than non-anxious subjects. Recent work has shown that some dietary polyphenols have both anxiolytic and antioxidant effects, which may be beneficial to anxious subjects


The early days of virotherapy

Some viruses prefer to attack cancerous tissues rather than healthy ones, and oncolytic virotherapy takes advantage of this fact. Anticancer viruses not only kill off tumor cells but also alert the host immune system to a cancer’s presence.

“Our immune systems have evolved over millennia to recognize pathogens very well — they have not evolved to recognize tumors very well,” said Dr. Antonio Chiocca, neurosurgeon-in-chief and chairman of the department of neurosurgery at Brigham and Women’s Hospital in Boston. Chiocca studies oncolytic viruses, or viruses that infect and kill cancer cells, which can likely be used in the treatment of brain cancer.

“The idea is very simply to place a viral infection in the tumor to alert the immune system,” he said. “Wake it up to the fact that there’s a tumor there.”

Scientists began experimenting with this type of immunotherapy as early as the late 1800s, but over the next 100 years, the field fell in and out of fashion. 

In the early 1900s, a surgeon named William Coley became famous for his attempts to fight cancer  by exposing patients to extractions drawn from infected tissue. Coley became hooked on the concept after meeting a man whose malignant tumor withered in the face of a severe bacterial infection, according to a review in BMJ Postgraduate Medical Journal. Coley began infecting his patients with a bacterial savior — the erysipelas virus — and later developed a vaccine from two modified bacteria.

“Coley’s toxins,” as the vaccine was called, became a popular treatment for many cancer types and worked by inducing fever, chills and inflammation in the patient. Numerous case studies supported the idea that infectious disease could send cancer into remission, or eliminate it completely, according to a review in the journal Molecular Therapy. But with the rise of radiotherapy, chemotherapy and other immunosuppressive treatments, emerging virotherapies like Coley’s toxins lost popularity. 

A second virotherapy outbreak

The development of tissue-culture systems and rodent cancer models in the 1940s and ’50s sparked a resurgence of virotherapy research, according to a review in the journal Nature Biotechnology. Doctors infected hundreds of cancer patients in clinical trials, exposing them to the mumps, hepatitis and West Nile. Success varied widely between trials. Some patients’ tumors regressed dramatically and their lives were prolonged. Others fought off the infection too quickly to reap its benefits, while still other patients emerged tumor-free, but later fell victim to the virus itself rather than their cancer. 

The 1980s ushered in the modern era of oncolytic virotherapy, and since then, the field’s prospects have been looking up.  

“Molecular virology came into play, and people discovered that certain viruses would replicate better in cancer cells than [in] their normal counterparts,” said Grant McFadden, the director of the Biodesign Center for Immunotherapy, Vaccines and Virotherapy at Arizona State University.

When cells become cancerous, he said, they gain dangerous features at the expense of beneficial features found in healthy cells. 

“Cancer cells gradually lose their ability to protect themselves from viral infection,” he said. “It’s that ‘Achilles’ heel’ that oncolytic viruses exploit.”

With the help of modern genetic engineering, researchers now strive to build the best oncolytic virus they can and then match the virus with its cancerous archnemesis.

Hurdles to clear

The field of virotherapy has significantly advanced in the past few decades, but the research remains difficult.

“The challenge is picking the right virus, deciding how to arm it and how to deliver it,” McFadden said. Some virotherapies can be injected directly into a tumor bed, making delivery a breeze. But many cancers are difficult to reach with a needle, or they might be scattered throughout the body. “This delivery problem is a major challenge,” McFadden said.   

Oncolytic viruses also have the potential to morph into “runaway viruses” — viruses that adapt after administration or recombine with human pathogens already present in a patient and begin ferociously infecting healthy tissue. Researchers remain on the lookout for these runaways, but so far, oncolytic viruses appear safe even in immunosuppressed patients and animal models, according to a 2014 review published in the journal Cell Host Microbe.

Anticancer viruses can now be engineered to selectively attack cancer cells, spare normal tissue, awaken the host immune system and reverse immunosuppression in the tumor microenvironment. But virotherapy is not a cure on its own. Research suggests that virotherapies will serve to supplement chemotherapy, radiation therapy or immunotherapy.

“Generally, in clinical trials the most promising treatment regime has been to combine virotherapy with an immune checkpoint inhibitor,” Chiocca said. Checkpoint inhibitors work by making tumors vulnerable to attack by the immune system, so pairing the treatment with an oncolytic virus can significantly boost its efficacy.

The future of cancer treatment 

In 2005, China’s State Food and Drug Administration — now known as the China Food and Drug Administration — put the first oncolytic virotherapy on the market. H101, commercially known as Oncorine, is a genetically modified virus that preferentially attacks tumor cells and is used to treat head and neck cancers.

The melanoma treatment T-VEC, made from a modified herpes virus, became the first FDA-approved virotherapy in 2015 and was approved in Australia and the European Union the following year.

More and more reports of promising virotherapy candidates have come out in recent years, according to an article published this year in the journal Nature Reviews Clinical Oncology.

Anticancer viruses can now be crafted from once-dangerous human viruses, such as measles, or nonpathogenic viruses. Even some viruses specific to animals have been tapped for virotherapy. For example, McFadden aims to develop a virus called the myxoma virus (MYXV), found only in rabbits, for therapeutic use in people.

As diligent scientists search for powerful oncolytic viruses, the field of virotherapy seems destined to continue to expand.

Serotonin deficiency could explain ‘imaginary’ somatic condition

When a person feels pain and doctors can’t figure out why, they often tell the person that their symptoms are psychological. A recently discovered biological cause could change the narrative.

woman experiencing neck pain seen from the back

People with heightened somatic awareness often experience pain in the neck and back.

Being told that one’s symptoms are a figment of one’s imagination can be a torment. But this is often the experience of people with one condition in particular.

Heightened somatic awareness has more than one name in the medical world. It is also known as bodily distress, functional disorders, or even “medically unexplained symptoms.”

Experts define it as pain that has no detectable physiological cause.

The most common symptoms of heightened somatic awareness tend to be headaches, fatigue, painful muscles and joints, and stomach trouble. Some people also report memory impairment, dizziness, and breathlessness.

People with heightened somatic awareness are twice as likely to experience chronic pain, and they often receive diagnoses of conditions such as irritable bowel syndrome, fibromyalgia, and rheumatoid arthritis. Some people may never get an accurate diagnosis, resulting in increased levels of distress.

The cause of heightened somatic awareness is unclear. Experts have named everything from hereditary factors and brain malfunctions to life stressors as potential causes.

Some healthcare professionals still see it as a psychological problem and recommend cognitive behavioral therapy, commonly called CBT, as an unmedicated treatment.

However, a team helmed by researchers at McGill University, in Montreal, Canada, has now found a potential biological cause of the condition. Their findings are published in the journal Annals of Neurology.

A biological cause

Samar Khoury, Ph.D., from McGill University’s Alan Edwards Centre for Research on Pain likens the findings to the tale of “The Princess and the Pea.”

“The princess in the story had extreme sensitivity, where she could feel a small pea through a pile of 20 mattresses,” says Khoury, who is the first author of the study.

“This is a good analogy of how someone with heightened somatic awareness might feel; they have discomforts caused by a tiny pea that doctors can’t seem to find or see, but which is very real.”

The results of the team’s study may provide proof that the pea exists — that symptoms of heightened somatic awareness aren’t imaginary.

Healthstead Global Limited Partnered with Vps Healthcare UAE

VPS Healthcare
Healthstead global Limited is extending her frontiers beyond and expanding her horizon in the international boundaries by clipping up with the Western Asia continent and Europe continent